Immunotherapy with 4-1BBL-Expressing iPS Cell‐Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma
Abstract
:1. Introduction
2. Results
2.1. Characterization of Mouse iPS-ML and iPS-ML-41BBL
2.2. Cytokine Analysis after Coculture of iPS-ML and Mouse Spleen Cells
2.3. iPS-ML-41BBL Inhibits Peritoneal Dissemination of Mouse Melanoma
2.4. iPS-ML-41BBL Induce Changes in TILs
2.5. In Vivo Priming of iPS-ML-41BBL Therapy
2.6. Antigen Presenting Ability of the iPS-ML-41BBL
2.7. Infiltration of iPS-ML in Established Tumor Tissue
2.8. ES-ML (129)-41BBL Suppresses the Peritoneal Dissemination of MO4 Melanoma
2.9. Autoimmune Reactions after iPS-ML-41BBL Therapy
3. Discussion
4. Materials and Methods
4.1. Cells and Culture Conditions
4.2. Mice
4.3. Flow Cytometry (FCM)
4.4. Generation of Genetically Modified 4-1BBL-Expressing iPS-ML (iPS-ML-41BBL)
4.5. Cytokine Production, ELISA, and Cytokine Array of Cocultured iPS-ML and the Mouse Spleen Cells
4.6. In Vivo Antitumor Activity of iPS-ML against MO4
4.7. OVA Tetramer Assay
4.8. Functional Analysis of TILs
4.9. Immunofluorescence Staining
4.10. PKH67 Labeling
4.11. Antigen-Presentation Assays
4.12. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723. [Google Scholar] [CrossRef]
- Hodi, F.S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Rutkowski, P.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19, 1480–1492. [Google Scholar] [CrossRef]
- Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [Google Scholar] [CrossRef]
- Teng, M.W.; Ngiow, S.F.; Ribas, A.; Smyth, M.J. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015, 75, 2139–2145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Phan, G.Q.; Rosenberg, S.A. Adoptive cell transfer for patients with metastatic melanoma: The potential and promise of cancer immunotherapy. Cancer Control 2013, 20, 289–297. [Google Scholar] [CrossRef] [PubMed]
- Imamura, Y.; Tashiro, H.; Tsend-Ayush, G.; Haruta, M.; Dashdemberel, N.; Komohara, Y.; Tsuboki, J.; Takaishi, K.; Ohba, T.; Nishimura, Y.; et al. Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta. Cancer Sci. 2018, 109, 3403–3410. [Google Scholar] [CrossRef]
- Miyashita, A.; Fukushima, S.; Nakahara, S.; Kubo, Y.; Tokuzumi, A.; Yamashita, J.; Aoi, J.; Haruta, M.; Senju, S.; Nishimura, Y.; et al. Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons. Cancer Immunol. Res. 2016, 4, 248–258. [Google Scholar] [CrossRef] [Green Version]
- Tsuchiya, N.; Zhang, R.; Iwama, T.; Ueda, N.; Liu, T.; Tatsumi, M.; Sasaki, Y.; Shimoda, R.; Osako, Y.; Sawada, Y.; et al. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1. Cell Rep. 2019, 29, 162–175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haruta, M.; Tomita, Y.; Yuno, A.; Matsumura, K.; Ikeda, T.; Takamatsu, K.; Haga, E.; Koba, C.; Nishimura, Y.; Senju, S. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther. 2013, 20, 504–513. [Google Scholar] [CrossRef]
- Alderson, M.R.; Smith, C.A.; Tough, T.W.; Davis-Smith, T.; Armitage, R.J.; Falk, B.; Roux, E.; Baker, E.; Sutherland, G.R.; Din, W.S. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 1994, 24, 2219–2227. [Google Scholar] [CrossRef]
- Langstein, J.; Michel, J.; Fritsche, J.; Kreutz, M.; Andreesen, R.; Schwarz, H. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J. Immunol. 1998, 160, 2488–2494. [Google Scholar] [PubMed]
- Goodwin, R.G.; Din, W.S.; Davis-Smith, T.; Anderson, D.M.; Gimpel, S.D.; Sato, T.A.; Maliszewski, C.R.; Brannan, C.I.; Copeland, N.G.; Jenkins, N.A. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 1993, 23, 2631–2641. [Google Scholar] [CrossRef]
- Hurtado, J.C.; Kim, Y.J.; Kwon, B.S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 1997, 158, 2600–2609. [Google Scholar] [PubMed]
- Shuford, W.W.; Klussman, K.; Tritchler, D.D.; Loo, D.T.; Chalupny, J.; Siadak, A.W.; Brown, T.J.; Emswiler, J.; Raecho, H.; Larsen, C.P.; et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 1997, 186, 47–55. [Google Scholar] [CrossRef]
- Sakellariou-Thompson, D.; Forget, M.A.; Creasy, C.; Bernard, V.; Zhao, L.; Kim, Y.U.; Hurd, M.W.; Uraoka, N.; Parra, E.R.; Kang, Y.; et al. 4-1BB Agonist Focuses CD8. Clin. Cancer Res. 2017, 23, 7263–7275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Melero, I.; Shuford, W.W.; Newby, S.A.; Aruffo, A.; Ledbetter, J.A.; Hellström, K.E.; Mittler, R.S.; Chen, L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997, 3, 682–685. [Google Scholar] [CrossRef]
- Houot, R.; Goldstein, M.J.; Kohrt, H.E.; Myklebust, J.H.; Alizadeh, A.A.; Lin, J.T.; Irish, J.M.; Torchia, J.A.; Kolstad, A.; Chen, L.; et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009, 114, 3431–3438. [Google Scholar] [CrossRef] [Green Version]
- Curran, M.A.; Kim, M.; Montalvo, W.; Al-Shamkhani, A.; Allison, J.P. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE 2011, 6, e19499. [Google Scholar] [CrossRef] [PubMed]
- Belcaid, Z.; Phallen, J.A.; Zeng, J.; See, A.P.; Mathios, D.; Gottschalk, C.; Nicholas, S.; Kellett, M.; Ruzevick, J.; Jackson, C.; et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS ONE 2014, 9, e101764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chester, C.; Sanmamed, M.F.; Wang, J.; Melero, I. Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies. Blood 2018, 131, 49–57. [Google Scholar] [CrossRef] [PubMed]
- Pérez-Ruiz, E.; Etxeberria, I.; Rodriguez-Ruiz, M.E.; Melero, I. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Clin. Cancer Res. 2017, 23, 5326–5328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tau, G.Z.; Cowan, S.N.; Weisburg, J.; Braunstein, N.S.; Rothman, P.B. Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells. J. Immunol. 2001, 167, 5574–5582. [Google Scholar] [CrossRef] [Green Version]
- Du, R.; Petritsch, C.; Lu, K.; Liu, P.; Haller, A.; Ganss, R.; Song, H.; Vandenberg, S.; Bergers, G. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008, 10, 254–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nishimura, M.; Umehara, H.; Nakayama, T.; Yoneda, O.; Hieshima, K.; Kakizaki, M.; Dohmae, N.; Yoshie, O.; Imai, T. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 2002, 168, 6173–6180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Clarke, S.R.; Barnden, M.; Kurts, C.; Carbone, F.R.; Miller, J.F.; Heath, W.R. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol. Cell Biol. 2000, 78, 110–117. [Google Scholar] [CrossRef]
- Mendes, O.; Kim, H.T.; Stoica, G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin. Exp. Metastasis 2005, 22, 237–246. [Google Scholar] [CrossRef]
- Nishida, M.; Okumura, Y.; Ozawa, S.; Shiraishi, I.; Itoi, T.; Hamaoka, K. MMP-2 inhibition reduces renal macrophage infiltration with increased fibrosis in UUO. Biochem. Biophys. Res. Commun. 2007, 354, 133–139. [Google Scholar] [CrossRef]
- Taube, J.M.; Anders, R.A.; Young, G.D.; Xu, H.; Sharma, R.; McMiller, T.L.; Chen, S.; Klein, A.P.; Pardoll, D.M.; Topalian, S.L.; et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4, 127ra137. [Google Scholar] [CrossRef] [Green Version]
- Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20, 5064–5074. [Google Scholar] [CrossRef] [Green Version]
- Sułkowski, M.; Konieczny, P.; Chlebanowska, P.; Majka, M. Introduction of Exogenous HSV-TK Suicide Gene Increases Safety of Keratinocyte-Derived Induced Pluripotent Stem Cells by Providing Genetic “Emergency Exit” Switch. Int. J. Mol. Sci. 2018, 19, 197. [Google Scholar] [CrossRef] [Green Version]
- Haga, E.; Endo, Y.; Haruta, M.; Koba, C.; Matsumura, K.; Takamatsu, K.; Ikeda, T.; Nishimura, Y.; Senju, S. Therapy of peritoneally disseminated colon cancer by TAP-deficient embryonic stem cell-derived macrophages in allogeneic recipients. J. Immunol. 2014, 193, 2024–2033. [Google Scholar] [CrossRef]
- Araki, R.; Uda, M.; Hoki, Y.; Sunayama, M.; Nakamura, M.; Ando, S.; Sugiura, M.; Ideno, H.; Shimada, A.; Nifuji, A.; et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494, 100–104. [Google Scholar] [CrossRef] [PubMed]
- Zhang, R.; Liu, T.Y.; Senju, S.; Haruta, M.; Hirosawa, N.; Suzuki, M.; Tatsumi, M.; Ueda, N.; Maki, H.; Nakatsuka, R.; et al. Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells. Cancer Immunol. Res. 2015, 3, 668–677. [Google Scholar] [CrossRef] [Green Version]
- Hogquist, K.A.; Jameson, S.C.; Heath, W.R.; Howard, J.L.; Bevan, M.J.; Carbone, F.R. Pillars article: T cell receptor antagonist peptides induce positive selection. Cell 1994, 76, 17–27. J. Immunol. 2012, 188, 2046–2056. [Google Scholar]
- Thevenot, P.T.; Sierra, R.A.; Raber, P.L.; Al-Khami, A.A.; Trillo-Tinoco, J.; Zarreii, P.; Ochoa, A.C.; Cui, Y.; Del Valle, L.; Rodriguez, P.C. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 2014, 41, 389–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kanemaru, H.; Yamane, F.; Fukushima, K.; Matsuki, T.; Kawasaki, T.; Ebina, I.; Kuniyoshi, K.; Tanaka, H.; Maruyama, K.; Maeda, K.; et al. Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages. Proc. Natl. Acad. Sci. USA 2017, 114, E7331–E7340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kuriyama, H.; Fukushima, S.; Kimura, T.; Kanemaru, H.; Miyashita, A.; Okada, E.; Kubo, Y.; Nakahara, S.; Tokuzumi, A.; Nishimura, Y.; et al. Immunotherapy with 4-1BBL-Expressing iPS Cell‐Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma. Int. J. Mol. Sci. 2021, 22, 1958. https://doi.org/10.3390/ijms22041958
Kuriyama H, Fukushima S, Kimura T, Kanemaru H, Miyashita A, Okada E, Kubo Y, Nakahara S, Tokuzumi A, Nishimura Y, et al. Immunotherapy with 4-1BBL-Expressing iPS Cell‐Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma. International Journal of Molecular Sciences. 2021; 22(4):1958. https://doi.org/10.3390/ijms22041958
Chicago/Turabian StyleKuriyama, Haruka, Satoshi Fukushima, Toshihiro Kimura, Hisashi Kanemaru, Azusa Miyashita, Etsuko Okada, Yosuke Kubo, Satoshi Nakahara, Aki Tokuzumi, Yuki Nishimura, and et al. 2021. "Immunotherapy with 4-1BBL-Expressing iPS Cell‐Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma" International Journal of Molecular Sciences 22, no. 4: 1958. https://doi.org/10.3390/ijms22041958